Stephen Basil Thomas - 27 Jun 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Role
Director
Signature
/s/ Chandra Adams, as Attorney-in-Fact
Issuer symbol
CLYM
Transactions as of
27 Jun 2025
Net transactions value
$0
Form type
4
Filing time
01 Jul 2025, 16:32:24 UTC
Previous filing
05 Jun 2025
Next filing
11 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thomas Stephen Basil Director C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS /s/ Chandra Adams, as Attorney-in-Fact 01 Jul 2025 0002027962

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Options Exercise +25,094 +14% 204,282 27 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLYM Restricted Stock Units Options Exercise $0 -25,094 -100% $0.000000 0 27 Jun 2025 Common Stock 25,094 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and vested as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

Remarks:

Exhibit Index: 24.1 - Power of Attorney